On Friday, Beyond Air (NASDAQ:XAIR) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data
Companies Reporting Before The Bell • Beyond Air (NASDAQ:XAIR) is estimated to report quarterly loss at $0.56 per share on revenue of $2.30 million. • Apogee Enterprises (NASDAQ:APOG) is expected to report quarterly
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
The global financial markets are currently gripped by a palpable sense of unease, as significant stock swings and heightened volatility define the investment landscape of late 2025. This turbulent period is primarily driven by a complex interplay of geopolitical tensions, evolving interest rate expectations, and lingering concerns over inflated valuations
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company at the forefront of nitric oxide (NO) therapies, announced on November 5, 2025, a significant financing deal of up to $32 million with Streeterville Capital. This strategic financial infusion, comprising a $12 million promissory note and a $20 million
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
